Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 35

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 35
---
, financial condition, operating results and cash flow.

<div align='center'>S-20

USE OF PROCEEDS</div>

We estimate the net proceeds to us from this offering
will be approximately $908,627.28 after deducting the Placement Agent fees and estimated offering expenses payable by us. We intend to
use the net proceeds from this offering for general corporate purposes, including working capital.

The amount, timing and nature of specific expenditures of net proceeds from this offering will depend on a number of factors, including the timing, scope, progress and results of our development efforts and the timing and progress of any collaboration efforts. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses of the proceeds from this offering. Accordingly, we will retain broad discretion over the use of such proceeds.

<div align='center'>DIVIDEND POLICY</div>

We have not declared any cash dividends since inception and we do not anticipate paying any dividends in the foreseeable future. Instead, we anticipate that all of our earnings will be used to provide working capital, to support our operations, and to finance the growth and development of our business, including potentially the acquisition of, or investment in, businesses, technologies or products that complement our existing business. The payment of dividends is within the discretion of the Board and will depend on our earnings, capital requirements, financial condition, prospects, applicable Delaware law, which provides that dividends are only payable out of surplus or current net profits, and other factors our Board might deem relevant. There are no restrictions that currently limit our ability to pay dividends on our common stock other than those generally imposed by applicable state law.

<div align='center'>CAPITALIZATION</div>

The following table sets forth our consolidated cash and capitalization, as of September 30, 2024. Such information is set forth on the following basis:

| ● | on an actual basis; |

| ● | on a pro forma basis to reflect the issuance of (i) 79,040 shares issued to our officers as 2024 bonuses, (ii) 2,454,551 shares issued for the exercise of 2,454,551 pre-funded warrants after September 30, 2024 but prior to the date of this prospectus supplement and (iii) 1,021,549 shares of common stock issued in the January 2025 Offering based on the offering price of $1.021 per share of common stock; and |

| ● | on a pro forma as adjusted